Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation.
interventional radiology
large animal model
liver cancer
personalized medicine
transgenic pigs
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
14 Jul 2020
14 Jul 2020
Historique:
received:
13
04
2020
accepted:
01
06
2020
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
1
8
2020
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. New animal models that faithfully recapitulate human HCC phenotypes are required to address unmet clinical needs and advance standard-of-care therapeutics. This study utilized the Oncopig Cancer Model to develop a translational porcine HCC model which can serve as a bridge between murine studies and human clinical practice. Reliable development of Oncopig HCC cell lines was demonstrated through hepatocyte isolation and Cre recombinase exposure across 15 Oncopigs. Oncopig and human HCC cell lines displayed similar cell cycle lengths, alpha-fetoprotein production, arginase-1 staining, chemosusceptibility, and drug metabolizing enzyme expression. The ability of Oncopig HCC cells to consistently produce tumors
Identifiants
pubmed: 32733642
doi: 10.18632/oncotarget.27647
pii: 27647
pmc: PMC7367657
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2686-2701Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Ron C. Gaba receives research support from Guerbet USA LLC, Janssen Research & Development LLC, the United States Department of Defense, and the United States National Institutes of Health. F. Edward Boas is a co-founder of Claripacs, LLC. He received research funding (investigator-initiated) from Guerbet. He received research support (investigator-initiated) from GE. He received research supplies (investigator-initiated) from Bayer. He received a research grant and speaker fees from Society of Interventional Oncology, which were sponsored by Guerbet. He attended research meetings sponsored by Guerbet. He is an investor in Labdoor, Qventus, CloudMedx, Notable Labs, and Xgenomes. He is the inventor and assignee on US patent 8233586, and is an inventor on US provisional patent applications 62/754,139 and 62/817,116. Regina M. Schwind receives research support from Guerbet USA LLC and Janssen Research & Development LLC. Lawrence B. Schook research support from Guerbet USA LLC, Janssen Research & Development LLC, the United States Department of Defense, and the United States National Institutes of Health. Kyle M. Schachtschneider receives research support from Guerbet USA LLC, Janssen Research & Development LLC, and the United States National Institutes of Health. The remaining authors—Lobna Elkhadragy, Sulalita Chaki, Hanna H. Chen, Mohammed El-Kebir, Kelly D. Garcia, Eileena F. Giurini, Grace Guzman, Francesca V. LoBianco, Mario F. Neto, Jordan L. Newson, Aisha Qazi, Maureen Regan, Lauretta A. Rund, Matthew C. Stewart, Faith M. Thomas, Herbert E. Whiteley, and Jiaqi Wu—have no reported conflicts of interest.
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Exp Biol Med (Maywood). 2004 Oct;229(9):866-75
pubmed: 15388881
Am J Transl Res. 2014 Jan 15;6(2):114-8
pubmed: 24489990
Cardiovasc Intervent Radiol. 2006 May-Jun;29(3):420-8
pubmed: 16502159
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Front Oncol. 2017 Aug 23;7:190
pubmed: 28879168
Oncotarget. 2017 Jun 29;8(38):63620-63634
pubmed: 28969016
Oncology. 2016;91(2):90-100
pubmed: 27305144
Biochem Pharmacol. 2012 Jul 15;84(2):215-23
pubmed: 22513143
Pharmacogenet Genomics. 2011 Mar;21(3):152-61
pubmed: 20216335
Expert Opin Drug Metab Toxicol. 2013 Mar;9(3):237-52
pubmed: 23256482
Kurume Med J. 2004;51(1):25-33
pubmed: 15150897
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
J Hepatol. 2011 Dec;55(6):1332-8
pubmed: 21703190
Nat Protoc. 2015 Aug;10(8):1264-74
pubmed: 26203823
EMBO Mol Med. 2016 May 02;8(5):442-57
pubmed: 26992833
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Oncologist. 2007 Apr;12(4):426-37
pubmed: 17470685
Nat Commun. 2020 Sep 2;11(1):4301
pubmed: 32879317
Bioinformatics. 2018 Jan 15;34(2):330-337
pubmed: 29028923
J Vasc Interv Radiol. 1999 Jun;10(6):793-8
pubmed: 10392950
Tumour Biol. 2017 Mar;39(3):1010428317695923
pubmed: 28347231
J Vasc Interv Radiol. 2018 Aug;29(8):1194-1202.e1
pubmed: 29887183
Eur Radiol. 2009 May;19(5):1049-53
pubmed: 19137307
Drug Metab Dispos. 2011 Nov;39(11):2130-4
pubmed: 21795467
Nucleic Acids Res. 2018 Jul 2;46(W1):W242-W245
pubmed: 29762716
Drug Metab Dispos. 2008 Oct;36(10):2113-20
pubmed: 18635746
Expert Opin Drug Discov. 2016 Dec;11(12):1131-1134
pubmed: 27546211
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Clin Gastroenterol Hepatol. 2015 Nov;13(12):2140-51
pubmed: 26284591
Nat Biotechnol. 2016 Jul 12;34(7):695-7
pubmed: 27404874
Biomed Res Int. 2013;2013:692071
pubmed: 23984399
Nat Methods. 2018 Aug;15(8):591-594
pubmed: 30013048
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Biomark Cancer. 2017 Feb 28;9:1-9
pubmed: 28469485
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2650-2666
pubmed: 31401364
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Pharmacol Ther. 2005 Apr;106(1):97-132
pubmed: 15781124
Diagn Interv Radiol. 2014 Jul-Aug;20(4):335-40
pubmed: 24834491
Oncology. 2018;95(6):360-369
pubmed: 30269135
PLoS One. 2015 Jul 01;10(7):e0128864
pubmed: 26132737